Clicky

Aldeyra Therapeutics, Inc.(ALDX)

Description: Aldeyra Therapeutics, Inc. (Aldeyra) is a biotechnology company. The Company is focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The Company is developing NS2. NS2 is a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of diseases, which include Sjogren-Larsson Syndrome (SLS), discoid lupus, acute anterior uveitis and ocular rosacea with meibomian gland dysfunction. Aldeyra is also developing aldehyde traps distinct from NS2. As of April 7, 2014, it had evaluated NS2 in a Phase I clinical trial in 48 volunteers.


Keywords: Medicine Biotechnology Disease Organ Systems Autoimmune Disease Rare Diseases Dysfunction Inflammatory Systemic Lupus Erythematosus Lupus Uveitis Syndromes Rosacea Discoid Lupus Meibomian Gland Meibomian Gland Dysfunction Ns2

Home Page: www.aldeyra.com

ALDX Technical Analysis

131 Hartwell Avenue
Lexington, MA 02421
United States
Phone: 781 761 4904


Officers

Name Title
Dr. Todd C. Brady M.D., Ph.D. CEO, Pres & Director
Dr. Stephen G. Machatha Ph.D. Chief Devel. Officer
Mr. Bruce Greenberg CPA, M.B.A. VP of Fin., Interim CFO & Treasurer
Mr. Kelly Mizer VP of Commercial Strategy & Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.2385
Price-to-Sales TTM: 0
IPO Date: 2014-05-02
Fiscal Year End: December
Full Time Employees: 15
Back to stocks